#United States #New York #Kidney Foundation #EGFR #Medication Decision

National Kidney Foundation Advocates for Race-Agnostic eGFR

In a landmark move for kidney care in the United States, leading pharmacy organizations have joined forces with the National Kidney Foundation (NKF) to advocate for a significant transition in medication decision-making. Their goal is to adopt a race-free estimated glomerular filtration rate (eGFR), considered a more accurate measure of kidney function, adjusted for body surface area.

Why This Significant Change?

The shift towards a race-agnostic eGFR is the result of a comprehensive multi-organization consensus statement which outlines the importance of modernizing kidney function assessments. The previous method, the Cockcroft-Gault equation, has been in use for almost fifty years and emphasizes a simplistic two-racial-category classification. According to Dr. Joseph Vassalotti, NKF’s Chief Medical Officer, these methods inherently introduce biases that affect global patient care. The new guidelines aim to improve medication prescriptions and enhance equity in treatment.

The recommended replacements include recently developed eGFR equations that utilize the 2021 CKD-EPI formula, a method validated against current clinical standards. Changing the standard to the race-agnostic approach means a more accurate, consistent, and clinically equitable assessment of kidney function, ultimately impacting how healthcare professionals prescribe medications.

Addressing Limitations of Previous Methods

While the Cockcroft-Gault equation was widely accepted, its limitations are becoming increasingly evident, especially in our diverse society. Developed using a limited sample from white males, it fails to represent a broader population, leading to potential misdiagnoses or incorrect medication dosages. The NKF's coalition believes that race-agnostic eGFR provides the precision necessary for modern healthcare, especially given the changes in population diversity, lab practices, and clinical guidelines.

As Andrew Bzowyckyj, a senior scientific director at NKF, stated, “Relying on outdated equations endangers patient safety.” The adoption of race-agnostic eGFR is more than a procedural shift—it's about ensuring that every patient receives tailored, evidence-based care.

Advancing Healthcare Equity

In urging this transition, the NKF highlights that healthcare must evolve in tandem with demographics and scientific advancement. With an estimated 1 in 7 adults in the U.S. affected by chronic kidney disease (CKD), of whom 90% are unaware, this initiative is crucial for better health outcomes. The disparity in risk factors among minority groups—like the increased rates of kidney failure among Black individuals—demands a new approach that leverages current best practices to ensure equitable access to care.

Organizations such as the American College of Clinical Pharmacy and the American Pharmacists Association are endorsing this change. These leaders in healthcare believe that adopting race-agnostic eGFR creates informed and equitable medication practices, ultimately benefiting all patients.

Moving Forward: A Call to Action

Implementation of these new guidelines will require collective action across various sectors, including clinicians, labs, educational bodies, and regulatory authorities. While the NKF acknowledges that widespread implementation will take time, momentum is already building in clinical practices and research environments.

This transition toward race-agnostic eGFR is a pivotal step closer to precision medicine in kidney care, marking a decisive shift towards accuracy and fairness in the treatment of kidney disease. Elizabeth Montgomery, NKF's National VP, emphasizes, “It’s time to utilize the better tools available to us today to enhance patient outcomes.”

In conclusion, the National Kidney Foundation and its partners advocate for an egalitarian approach to kidney health care, recognizing that every patient's treatment journey should be informed by the best available scientific evidence. This call to action is not only a push towards better healthcare practices but also a significant move towards abolishing systemic inequities in health care for kidney disease patients.